Higher expression of phosphodiesterase type 5 in the anterior fibromuscular stroma of the human prostate

[1] Gacci M(2011)Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia Eur Urol 60 809-825

[2] Eardley I(2004)Summary of the recommendations on sexual dysfunctions in men J Sex Med 1 6-23

[3] Giuliano F(2007)Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial J Urol 177 1071-1077

[4] Hatzichristou D(1998)Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5) Biochem Biophys Res Commun 247 249-254

[5] Kaplan SA(2004)Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa Endocrinology 145 2253-2263

[6] Maggi M(2001)Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate J Urol 166 2484-2490

[7] McVary KT(2007)Characterization and functional role of androgen-dependent PDE5 activity in the bladder Endocrinology 148 1019-1029

[8] Mirone V(2006)Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate Eur Urol 49 740-745

[9] Porst H(2010)Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia Endocrinology 151 3975-3984

[10] Roehrborn CG(1972)The prostate and prostatic urethra: a morphologic synthesis J Urol 107 1008-1016

[1] Gacci M(2011)Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia Eur Urol 60 809-825

[2] Eardley I(2004)Summary of the recommendations on sexual dysfunctions in men J Sex Med 1 6-23

[3] Giuliano F(2007)Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial J Urol 177 1071-1077

[4] Hatzichristou D(1998)Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5) Biochem Biophys Res Commun 247 249-254

[5] Kaplan SA(2004)Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa Endocrinology 145 2253-2263

[6] Maggi M(2001)Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate J Urol 166 2484-2490

[7] McVary KT(2007)Characterization and functional role of androgen-dependent PDE5 activity in the bladder Endocrinology 148 1019-1029

[8] Mirone V(2006)Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate Eur Urol 49 740-745

[9] Porst H(2010)Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia Endocrinology 151 3975-3984

[10] Roehrborn CG(1972)The prostate and prostatic urethra: a morphologic synthesis J Urol 107 1008-1016